SAN FRANCISCO, April 10, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it ...
A full clinical hold suspends dosing and enrollment in the Phase III HERO study and open-label extension, superseding the earlier voluntary pause and freezing near-term registrational timelines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results